Schizophrenia News

Analysis of a nationwide sample indicated exposure to atypical antipsychotics in the first trimester of pregnancy did not significantly increase risk for congenital malformations.

Alkermes recently announced the submission of a supplemental New Drug Application to the FDA for a 2-month dosing interval of Aristada extended-release injectable suspension for schizophrenia.

Allergan and Gedeon Richter recently released findings that indicated inefficacy of flexible doses of Vraylar as adjunctive treatment for treatment-resistant major depressive disorder.

Recent findings indicated antipsychotic polypharmacy among 12% of individuals discharged from a state psychiatric inpatient hospital.

Raloxifene hydrochloride, a selective estrogen receptor modulator with mixed agonist and antagonist activity, reduced illness severity and increased likelihood of clinical response in women with treatment-resistant schizophrenia, according to recent findings.

Recent findings indicated accuracy of a risk calculator for individual risk for conversion to psychosis among clinical high-risk individuals.

Exposure to violence increased risk for violent crime among individuals with and without psychotic disorders, and parental bereavement particularly increased risk for crime among those with schizophrenia.

Hypothyroxinemia during early to mid-gestation was associated with increased risk for schizophrenia in offspring, according to recent findings.

Recent findings indicated antidepressants added to antipsychotics for schizophrenia had small, beneficial effects with low risk for exacerbation of psychosis and adverse effects.

Individuals with an early history of heavy cannabis use have higher risk for death than those with no history of cannabis use, according to recent findings.